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Abstract 
In today's biopharmaceutical industries the lead time to develop and produce a new monoclonal 
antibody takes years before it can be launched commercially. The reasons lie in the complexity of the 
monoclonal antibodies and the need for high product quality to ensure clinical safety which has a 
significant impact on the process development time. Frameworks such as Quality by Design are 
becoming widely used by the pharmaceutical industries as they introduce a systematic approach for 
building quality into the product. However, full implementation of Quality by Design has still not been 
achieved due to attrition mainly from limited risk assessment of product properties as well as the large 
number of process factors affecting product quality that needs to be investigated during the process 
development. This has introduced a need for better methods and tools that can be used for early risk 
assessment and predictions of critical product properties and process factors to enhance process 
development and reduce costs. 
In this review we investigate how the Quantitative Structure-Activity Relationships framework can be 
applied to an existing process development framework such as Quality by Design in order to increase 
product understanding based on the protein structure of monoclonal antibodies. Compared to Quality 
by Design, where the effect of process parameters on the drug product are explored, Quantitative 
Structure-Activity Relationships gives a reversed perspective which investigates how the protein 
structure can affect the performance in different unit operations. This provides valuable information 
that can be used during the early process development of new drug products where limited process 
understanding is available.   
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Introduction 
Monoclonal antibodies (mAbs) are therapeutic proteins that have gained increasing importance over the 
years mainly due to their clinical specificity and safety in treatments, but also because they can be 
applied to a wide spectrum of different aliments. Their increasing popularity can be seen in recent 
reports on the market for mAbs where the sales have increased from around $39 billion in 2008 to 
around $75 billion in 2013, making mAbs one of the fastest growing bioproduct groups [1]. This has 
led to many advances in improving the mAb manufacturing processes in areas such as process 
optimization [2, 3] and process control [4] to bring down manufacturing costs and time to market. 
However, the process development for manufacturing of mAbs is cost- and time-intensive due to the 
high product quality requirements that must be met to make the product clinically safe for commercial 
use. This is especially pronounced for the downstream operations where intensive characterisation of 
the unit operations (UOs) are needed to ensure high product quality and purity of the end product [5, 
6].  
Paradigms such as Quality by Design (QbD) have become an integral part of process 
development in today’s biotech industries with the goal of obtaining a high and more constant product 
quality with less risk of batch failures [7, 8]. The QbD paradigm provides a work-flow of building 
quality into the product by placing emphasis on increasing the process understanding and investigating 
how process parameters (PPs) affect the final product quality. The implementation of the framework 
has been covered extensively in many reviews [7, 9-11]. Continuous improvements are constantly being 
made to increase the effectiveness and applicability of these frameworks for production of 
biopharmaceuticals [12, 13]. 
However, effective implementation of QbD is still proving to be a significant challenge in 
biopharmaceutical industries due to the complex relationships between process parameters and product 
quality, which need extensive experimental studies to be characterized [14]. Eon-Duval et al. [15] 
summarized the most common Critical Quality Attributes (CQAs) for mAbs in process development 
that are important to monitor and control and how different PPs such as temperature, pH and ionic 
strength can have an effect on the product quality. An example of this is the glycan structure of the 
mAbs which is important for the efficacy and stability of the protein and is therefore an important factor 
to monitor and control [16-18]. In 2012, Genentech & Roche attempted to file a QbD application for 
the antibody Perjeta (pertuzumab) to Food and Drug Administration (FDA) but the application was 
rejected due to the design space not being properly characterized [19]. The reasons included lack of 
thorough risk assessment and the failure to recognize important PPs in the bioreaction of the mAb 
synthesis, which introduced high variability in the glycan structure. This had an undesired effect on the 
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), which made the antibody clinically unsafe. 
Thus, further characterization studies were needed to identify the critical process parameters (CPPs) 
and their optimal ranges to maintain desired glycan structure. Studies have shown that increased control 
over the glycan structure can be gained through optimizing the composition of the basal and feed media 
[20-22] or improving the cell line used for expression [23] which can help to drive the glycosylation 
towards the desired quality. 
Sustained effort has gone into the development of more efficient high-throughput screening 
methods for both upstream and downstream operations to be able to perform more rigorous 
characterization studies. Many of these techniques are in small scale which helps to reduce the use of 
resources, costs and aids in speeding up process development [24], given that they are representative of 
the larger scale. This includes high-throughput screening of cell lines across different fed-batch scales 
[25], high-throughput development of media [26, 27], high-throughput process development using 
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small scale reactor systems [28] and high-throughput screening of exchange chromatographic columns 
[29, 30]. The use of statistical design of experiments (DoE) can generate qualitative and quantitative 
information about the system [31]. A well-chosen experimental design can provide diverse and 
informative data about the system and when combined with high-throughput experimentation 
techniques, it can be an efficient tool for defining the process design space [28, 32]. However, the 
knowledge that is captured in the data could not only be used for the characterisation of the design space 
of the current candidate, but also help to guide the development of process operations for similar future 
candidates via risk assessment. 
Focus of this review 
Process development of mAbs requires major investments from the pharmaceutical companies and they 
adopt the QbD paradigm because they expect that in the long term it will help to reduce the investments 
and reduce process development times. The idea is that a better understanding of the processes and 
products will allow reducing the experimental effort in the future. Today, the process and product 
knowledge is incorporated through risk assessment, specifying the product CQAs that need to be 
monitored and controlled within certain ranges, as well as listing process parameters that might have an 
impact on the specified CQAs. These assessments are usually based on experience from previous 
process developments of mAbs and literature research [33]. This is an iterative process, which requires 
a significant allocation of resources throughout process development and de novo for each new mAb.  
Zurdo [34] suggested that the QbD framework needed to be extended to incorporate product 
knowledge in the form of developability of pharmaceuticals which includes manufacturability, 
safety/pharmacology and biological activity. The author argued that by using risk assessment tools 
based on in silico methods, information concerning different CQAs can be inferred by correlating 
structural data from many pharmaceuticals to their behaviour. In a later publication by Zurdo et al. [8], 
two case studies were presented where structural properties of the pharmaceuticals were linked to CQAs 
such as aggregation and half-life, which were successfully predicted.  
Thus, the focus of this review explores the different aspects that need to be considered in order 
to produce in silco risk assessment tools for mAbs. In particular, the adoption of Quantitative Structure-
Activity Relationship (QSAR) type modelling is reviewed as a method to incorporate mAb specific 
aspects into the QbD paradigm. It is argued that such tools can greatly aid risk assessment in early 
process development when not much is known about either the process or the product behaviour in 
different UOs of the process, e.g. propensity to aggregate in downstream processing. The means by 
which these methods can more efficiently reuse historical data from previous UO characterization 
studies of other mAb platforms in order to correlate the effect of generated structural features/properties 
and PPs on the product quality are also addressed. The methods of predicting the change of CQAs with 
different protein structures are discussed and it is argued that the optimal ranges can be inferred for PPs 
that affect the specified CQAs based on the historical process development data. It is concluded that in 
turn this should aid in reducing the number of experiments required to characterize the process, thus 
saving cost and development time.  
Quantitative Structure-Activity Relationship (QSAR) 
The QSAR framework relates structural features or descriptors of a compound to biological or 
physicochemical activity [35, 36]. This methodology was first introduced by Hammet  [37] in the 1930s 
and was later refined by Hansch and Fujita and has become a standard tool for small drug discovery. A 
method derived from QSAR, referred to as Quantitative Sequence-Activity Modelling (QSAM), has 
been introduced in recent years and focuses on relating structural descriptors of proteins, peptides and 
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nucleic acids to activity [38]. Given the proteinaceous character of the mAbs, the QSAM methodology 
will be of more relevance and the workflow described below will therefore focus more on sequence 
based rather than small molecule based QSAR. The QSAR/QSAM framework have been applied to 
diverse range of challenges where structural properties of pharmaceuticals have been used directly for 
the prediction of different process related aspects such as the prediction of isotherm parameters in ion-
exchange chromatography [39], ligand-binding in ion-exchange chromatography under high salt 
concentrations [40], binding of proteins in ion-exchange chromatography in different pH conditions 
[41], protein surface patch analysis for the choice of purification methods [42], chromatographic 
separation of target proteins from host cell proteins (HCP) [43], viscosity, clearance and stability 
prediction for antibodies [44] and degradation prediction of asparagine and aspartate in antibodies [45] 
to mention a few. This also showcases one of the main strengths of the QSAR/QSAM framework with 
its ability to link structural features to many different forms of prediction outputs. It is important to note, 
however, that identical experiments must have been performed on different pharmaceuticals in order to 
compare the differences in structure and their effect on the output. Equally important is that sufficient 
excitation is present in the output data in order for the effects to be linked to the corresponding structural 
feature. 
A general outline of developing a QSAR model is presented in Figure 1. The structure of the 
outline is not representative for all types of data sets and will change depending on the area of 
application. It gives however, an overview of the vital components of the QSAR methodology which 
will be discussed further in the review. 
 
Figure 1. General outline of the QSAR model development. The represented structure is one of many possible layouts that 
can be used which depends on the type of the data, size of data set, number of descriptors, selection methods for descriptors, 
modelling method and goal of the model. However, the use of cross-validation and external testing should always be an integral 
part of all model construction to ensure high model quality and increase its ability to generalize when possible. 
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Descriptor generation 
One of the most important steps in QSAR/QSAM is how the structures of the pharmaceuticals in 
question can be described numerically in order to use them in correlation studies with prediction outputs 
of interest. For proteins such as mAbs two approaches to generate descriptors are discussed here: 1) 
descriptors generated from the amino acid primary sequence and 2) descriptors generated from three-
dimensional models of the antibodies. It has been shown that a combination of both physicochemical 
and 3D descriptors works best and also ensures that the model is not overly reliant on a single type of 
a descriptor [46]. The workflow for the generation and incorporation of descriptors into QSAR is 
illustrated in Figure 2.  
Amino acid composition-based descriptor generation 
Extensive research has been carried out to develop new informative descriptors for peptides and proteins 
generated from their primary sequence [47]. This was first introduced by Sneath [48] who derived 
amino acid descriptors for the 20 naturally occurring amino acids from qualitative data. Later on Kidera 
et al. [49] used 188 properties of the 20 naturally occurring amino acids, which were converted into ten 
orthogonal new descriptors to describe the amino acids. Later the z-scale which consists of 3 new amino 
acid descriptors derived by applying principal component analysis (PCA) on 29 physiochemical 
properties [50, 51], was introduced. Other amino acid scales, which were also derived through PCA, 
include the extended Z-scale [52] and T-scale [53]. Other descriptors include the so called isotropic 
surface area (ISA) and the electronic charge index (ECI), which are derived from the three-dimensional 
structures of the amino acids [54]. All these descriptors were tested and performed well in respective 
studies on small peptides [51-54].  In a two-part review by van Westen et al [55, 56] many of the existing 
amino acid scales were benchmarked and compared. The authors demonstrated that the different scales 
described different physiochemical and topological properties which is useful when deciding on which 
scales to use. Obrezanova et al. [57] used several such amino acid scales to predict mAb aggregation 
propensity based on the primary structures. Doutchinova et al. [58] applied the Z-scales descriptors to 
successfully predict ligand binding of peptides. However, even though amino acid descriptors explain 
differences in the primary structure, they do not take into consideration potential interaction between 
the amino acids in or between primary chains. It has been argued that this simplification can lead to a 
loss of information concerning properties of secondary and tertiary structure in larger proteins [47].  
Descriptors can also be generated by using empirical equations on the entire primary sequence 
to infer protein properties such as the isoelectric point, hydrophobicity, molecular weight, physico-
chemical properties and secondary structure content to name a few. Many such tools and applications 
are available on bioinformatics sites, such as ExPASy [59] and EMBL-EBI [60]. 
Homology modelling and molecular dynamics for descriptor generation 
Descriptors capturing structural and surfaces properties can be generated by using existing crystal or 
NMR structures or by building models using homology modelling. The latter is done by finding proteins 
with existing 3D structures that have a high level of similarity to the primary sequence of the protein of 
interest. These proteins are then used as templates to predict the likely structure of the queried protein 
[61]. This has been successfully used in many publications where information such as surface areas, 
angles and surface properties were extracted [43-45]. The method is especially useful when no crystal 
structure exists. Caution needs to be exercised, however, as the homology models are only predicted 
structures and might not represent the true protein conformation. Breneman et al. [62] introduced a 
methodology for generating 2D surface descriptors, also called transferable atom equivalent (TAE) 
descriptors, by reconstructing the electronic surface properties of the molecular structures from a library  
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Figure 2. Examples of different routes for descriptor generation using the primary sequence and crystal structure of the protein. The primary sequence can be used to generate both local and global 
descriptors with the use of amino acid scales for numerical conversion and homology modelling/MD simulations to simulate surface properties. Available structure from crystal X-ray or NMR 
can be incorporated together with generated homology models. The different descriptors can be used together with modelling methods such as those mentioned in this review to link the structure 
of the protein to characterization data.
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of atomic charge density components. This has the advantage of representing surface variations such as 
hydrophobicity and charge distributions numerically, which is of great importance when studying for 
example protein binding to an anion exchange chromatographic column packing using different salts 
[63]. Breneman et al. [64] later introduced the Property-Encoded Surface Translator (PEST) algorithm 
which is a further development to better describe the surfaces of the proteins when applying the TAE 
molecular surface descriptors. However, it is important to note that both TAE and PEST need 3D 
models in order to generate the descriptors of interest. PEST together with TAE descriptor, has been 
successfully applied in a QSAR study where the generated model was able to accurately predict protein 
separation from HCPs [43]. Robinson et al. [65] used the TAE descriptors to relate the structural 
differences between several Fab fragments to predict column performance between different 
chromatographic systems. It has been argued however that caution needs to be exercised when using 
library based descriptors as these are usually directly related to a specific state of a compound that was 
measured in a unique environment. This means that these descriptors should only be applied if 
experiments were carried out in an identical or similar environment. Otherwise, this might cause the 
descriptors to be biased [46]. Other structural properties, such as molecular angles and solvent 
accessible surface areas extracted from homology models, were used by Sydow et al. [45] to determine 
the risk of degradation of asparagine and aspartate in mAbs as post translation modifications. Similarly, 
Sharma et al. [44] investigated the risk of oxidation of surface accessible Tryptophans.  
Due to the flexibility and size of the antibodies it is very difficult to produce good 3D structures 
based on X-ray crystallography and NMR. Instead, homology modelling has proven to be a good 
alternative to circumvent this problem. However, due to the size and the many flexible parts, such as 
loops, in the antibodies, pure homology models might not give a sufficiently accurate representation of 
the reality. Molecular dynamics (MD) is a useful tool that can be used to minimize the energy of the 
entire protein and to simulate the dynamics of the protein of interest in different environments [66]. MD 
simulations have also shown very high similarities in the internal dynamics of antibodies when 
comparing the simulated results to those observed in reality [67]. It can therefore be argued that MD 
simulation should be applied to all homology models before descriptors are generated to mimic the 
environment of the samples that are used in QSAR studies. 
Table S1 shows a list of popular homology modelling and MD simulation software that has 
been used to generate 3D models of mAbs and extract descriptors. 
Descriptor Selection 
The descriptor generation usually results in a large number of descriptors being produced, requiring a 
descriptor subset selection such that the predictability of the QSAR model is increased by reducing 
noise and collinearity [68, 69]. This process is however very complex and despite extensive research, 
no clear workflows have yet been proposed. An established rule of thumb for building a good model is 
that the ratio between samples and descriptors should at least be five to one [68]. However, most studies 
struggle with a limited number of samples, which makes it hard to fulfil this condition. The choice of 
modelling method will have a great impact on this with methods like Support Vector Regression (SVR) 
and Partial Least Squares (PLS) being able to generate robust models even when the number of 
descriptors are greater than the number of samples [70, 71]. The performance of the selected descriptors 
is also dependent on the classifier that is used. An optimal combination is usually found through 
benchmarking different combinations of descriptor selection methods and modelling methods [72, 73]. 
It has also been shown that descriptor selection methods should not be purely data-driven but should 
also be based on prior knowledge and descriptors should be added if they are known to have an effect 
on the system [74].  
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The descriptor selection process can be separated into two parts; (1) dimensionality reduction 
before using the data in modelling and (2) model-based or algorithm-based descriptor selection when 
training the model, see Figure 1. In the first part, descriptor extraction and dimension reduction methods 
like PCA have proven to be an effective way to reduce collinearity in the initial descriptor set [75]. For 
the second part, many modelling methods have descriptor selection capability. For example, PLS 
weights the descriptor according to contribution to the model output, Support Vector Machines (SVM) 
select descriptors that can generate maximum distance between classes and Random Forest (RF) 
randomly selects descriptors to create unique trees for classification [76, 77]. Alternatively, there are 
algorithm-based selection methods such as forward selection or backward elimination where descriptors 
are added or eliminated from the model iteratively to reduce the modelling error and these are popular 
in QSAR studies [78]. For example, in the work of Chen et al. [79] the protein retention using 
hydrophobic interaction chromatography under different salt conditions was investigated. A sparse 
linear Support Vector Machines for Regression (SVR) algorithm was used for dimensionality reduction 
to select a subset of descriptors that had high correlation to the response before training a final nonlinear 
SVR model. For more extensive reviews on descriptor selection methods for QSAR refer to further 
literature, e.g. Shahlaei [68], Yousefinejad and Hemmateenejad [70] and Rudnicki et al. [80].  
Model Development and Validation 
Cross validation 
The development of the model is carried out by training a classifier or regression method with a 
calibration data set that traditionally consists of 70-80% of all the available samples which can be seen 
in Figure 1. This should always be carried out with a resampling method in the form of cross-validation 
(CV) to fully make use of the available samples to optimize model parameters. The main advantage of 
using resampling methods is the increase in confidence in the final model and this type of training is 
usually referred to as internal cross validation in QSAR [81]. A common method is k-fold CV which is 
used here to explain the model development methodology. K-fold CV divides the training data set in to 
k equally sized subsets and trains the model by using different permutations of these. One subset is 
always left out of the training and used instead to validate the generated model [82]. This generates k 
new models with respective performance metrics that have been trained with differing data sets that are 
used to identify optimal model parameters for the final model trained with the full training data set. The 
main advantage of this procedure is that over-fitting of the training data is avoided by minimizing the 
model error. The impact of outliers present in the data is reduced and the final model exhibits better 
generalization properties [83]. The remaining 20-30% of the samples are used to estimate the final 
models true accuracy when used on an external data set [83, 84]. There have been many studies where 
high prediction performance was reported from internal validation but no external validation had been 
performed and the model later failed to accurately predict new data [85, 86].  
Important to remember when dividing the data is that high enough variability of the compounds 
is present in the data set for training. The data set should contain sufficient distinct excitations in the 
variables to be able to describe the system behaviour which will be the foundation for the model 
applicability domain [87]. Therefore, exploratory analysis of the data is recommended as part of the 
model development, e.g. Principal Component Analysis [88],  before dividing the data into training and 
test sets. This is to ensure that all necessary information will be presented when developing the model 
as a model cannot extrapolate outside of the boundaries of the data used for its training. 
It has been argued that a better approach to the traditional model training regime is by using 
nested cross validation instead for machine learning methods such as SVM to find the optimal model 
hyper parameters. Like basic cross validation, nested cross validation has an internal cross validation 
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loop to train the model. The main difference is that instead of having a static external test set, an outer 
cross validation loop is used to provide data permutations for training and externally validating the 
model. This has the advantage of further reducing the model bias by using the full data set more 
efficiently but at the expense of being more computationally heavy [89]. 
However, caution needs to be exercised when dealing with small data sets as division into test 
and training sets can lead to loss of information when developing the model. In such cases, external 
validation based on the original data set will be difficult where selection of test data points might 
introduce bias into the model due to data sparsity. Bootstrap resampling which was first introduce by 
Bradely Efron in 1979 [90], has been shown to be a good method to counter this [91]. In bootstrapping, 
new data sets are generated by randomly selecting samples from the original data set where sample 
repetition is allowed. The selection continues until the new data set is of the same size of that of the 
original. The samples that are not selected in the new data set are used for validation instead. Due to the 
random selection, many unique permutations are generated which means that a more efficient training 
of the model with the available data set as well as information about descriptor uncertainty can be 
generated by investigating the contribution of each descriptor to the model performance of all models 
[92]. Another problem with small-sample sizes is that due to sparsity the sample population might not 
give accurate descriptor distribution estimates needed to classify the samples. Preferably, data generated 
from experimental designs would ensure high data excitation being present in the data set. 
Another approach instead of traditionally generating a single model as described above is to 
use an ensemble or aggregation of generated sub-models for prediction such as bootstrap aggregation 
(bagging) which was introduced by Leo Breiman [93]. For regression this would generate a mean value 
and for classification the most voted class would be chosen based on the used sub-models. Bagging also 
shows the uncertainty of predictions which can be assessed by investigating the prediction variation of 
all sub-models. This might be preferable if a single model shows high instability in prediction whereas 
model aggregation potentially can increase the model precision [94]. Bagging has been shown to be 
particularly efficient in training QSAR models in chromatography settings [40, 41, 95]. It has been 
argued however that caution needs to be exercised if specific sub-models are selected for the model 
aggregation which can introduce bias and reduce the models ability to generalize [83]. 
Model Performance 
There are numerous metrics that can be used to evaluate the model performance. In regression, the most 
commonly used metric is R2 or otherwise known as the goodness of fit of the model which ranges from 
zero where no output variation is explained, to one where all variation is explained [86]. Another 
important metric is the mean square error (MSE) which is a measure of the difference between the 
measured and predicted values. This metric is especially important when accounting for the model 
complexity in the internal cross validation e.g. selection of model parameters. The MSE for cross 
validation (MSECV) is generated from the differences between the predicted values and the measured 
samples in the validation sets. The MSE can be broken down into the three components: the squared 
model bias, the model variance (or the random error in the fitted model) and an irreducible error which 
will always be present [96]. The first two terms can be used for the bias-variance trade-off when 
optimizing the model fit. This means that the model parameters are chosen to minimize the sum of 
squared model bias and model variance in the MSECV. This ensures the highest generalization for the 
model with the specific cross validation method that was used. 
Metrics used for classification are different when compared to those of regression as the model 
fit might not necessarily correlate to the number of correctly predicted samples. Instead, metrics are 
derived from the classification confusion matrix are preferably used. This matrix is a square matrix 
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where the dimensions equal the number of assigned classes. The error rate, which is the number of 
misclassified sample gives a better representation for optimizing the model performance through cross 
validation compared to that of MSE is used in regression [97]. A popular metric that summarizes the 
different aspects in the confusion matrix is the Matthew’s correlation coefficient (MCC). It can be used 
to benchmark different models and it ranges from zero to one, meaning no correlation between 
descriptors and output to full correlation respectively [98]. 
Even with descriptor selection the number of descriptors that is used in the model training might 
still be extensive. In QSAR, Y-randomization has gained a lot of popularity and is used to investigate 
if random permutations of descriptors contribute to the model performance. The method works by 
randomizing the output between the samples and a model is generated as described above with the 
randomized data set. If random descriptor contributions affect the model performance in the external 
test set, then metrics like the goodness of fit (R2) for regression and MCC for classification will show 
high correlation (close to one). This means that either further descriptor selection needs to be performed 
or more samples are needed to increase the available information in the data set. If the values are close 
to zero however, this means that little to no random contribution from the descriptors occur and that the 
contributing descriptor from the original model have high correlation to the measured outputs [99]. 
Selecting a modelling method to be used in QSAR studies can be challenging. Usually trial and 
error prevail to select the model with highest accuracy and smallest error in order to get a good fit, 
which is usually done in the form of model benchmarking. To summarize, selection and training of the 
model must be executed with care as no one method or combination of methods works for all situations. 
If possible, the impact of the contributing descriptors on the model output should be investigated to see 
if there is a mechanistic explanation pertained to the descriptors and output, thus adding more credibility 
to the model. It is therefore important to remain critical of the generated models and thoroughly 
investigate their stability, precision and if the models make sense [100].  
An extensive, but non-exhaustive list of popular modelling methods that has been used in both 
QSAR and multivariate data analysis in process development is presented in Table S2 where advantages 
and disadvantages are listed for each method. This review however, is meant to inspire a greater 
understanding and good practices for developing models and the different aspects to consider when 
using QSAR for proteins such as mAbs. Therefore, further discussions or comparison of the different 
modelling methods is out of the scope if this review.  
Towards antibody process development by bridging QbD and QSAR 
There have been significant advances in computational prediction methods and they are starting to 
become more common in process development [101]. As mentioned by Zurdo et al. [8], the ability to 
predict product related characteristics that strongly relate to the QTPP and/or CQAs can greatly simplify 
process development, especially in the early stages when the product or process knowledge is limited. 
Implementation of QSAR in process related areas such as protein purification have been researched 
extensively, e.g. Chen et al. [95], Yang et al. [41], Ladiwala et al. [102], Woo et al. [103] and Robinson 
et al. [65] to mention a few. Though not all the mentioned examples concern mAbs specifically, the 
outlined methodology used in the different research articles is still applicable to antibodies. Given the 
significant proportion of mAb production cost that is incurred during downstream processing, 
considerable advantages can be gained by being able to predict the performance of chromatographic 
columns and their effect on product quality early in the process development. In the case of antibodies 
much of the cost is incurred during the purification due to the strict regulations surrounding clinical 
safety of the end product [5, 104].  
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A proposed integration of QSAR into QbD based on these concepts is illustrated in Figure 3 
which also shows how the QbD framework can add to and improve the QSAR modelling with addition 
of new data.  
 
Figure 3. Illustrates the integration of QSAR into QbD where the upper half of illustrates the simplified framework of QbD 
whereas the lower half illustrates a simplified version of the QSAR framework. The yellow arrows represent transfer of 
characterisation data from previous mAb processes that can be used directly for model development using QSAR. Developed 
QSAR models can be used to directly aid in assessing CQAs (red arrows) as well as provide insight into process parameters 
(grey arrows). 
Two main approaches of integrating the QSAR framework into the QbD paradigm can be 
considered. The first approach is by only using generated structural descriptors for development of 
models able to predict protein behaviours. An example of this was published by Obrezanova et al. [57] 
where the authors developed a model being able to predict the probability of mAb aggregation based 
on the structure of the primary sequence. The method is however more constrained as it requires data 
generated from identical experimental setups, and therefore identical PP settings in order to assume that 
the observed effect is caused only by the differences in structure between the proteins. Therefore, 
models developed this way are better for assessing the manufacturing feasibility and/or potential CQAs 
before starting the process development (seen as red arrow in Figure 3). The second approach is to use 
the PPs of interest, taken from previous mAb processes to use directly in the model development (seen 
as yellow arrows in Figure 3) by either 1) by adding the PPs together with the generated structural 
descriptors as inputs [105] or 2) structural descriptors are calculated to be dependent on the PPs, 
meaning that the values of the descriptors will change with changing values of the PPs [41]. The latter 
is easiest done by generating descriptor from MD simulations where changes in the soluble environment 
can be implemented. This however requires that data is gathered from similar experimental setups where 
only the PPs of interest have been varied. This would usually not be a problem when gathering historic 
data generated from the QbD paradigm as it will often conform to experimental designs based on DoE 
where the experimental environment is strictly controlled. The added benefit of this approach is that the 
developed model will be able to account for both the structural differences as well as the impact from 
the studied PPs when predicting protein behaviour. This can potentially have great value in process 
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development of new antibodies as PP ranges can be assessed in silico and therefore greatly aid in 
reducing the number of needed experiments, seen as grey arrows in Figure 3. 
The methods described above provide a reference for further risk assessment and 
characterization to be performed in the QbD framework, as they provide information, such as the 
behaviour of the product in different scenarios and increase the product understanding. As additional 
information from new mAb processes becomes available, models can be improved by expanding the 
datasets used in the model development. This in turn will aid in providing more accurate predictions 
due to lowering the sparsity by incorporating more protein structures. Available characterization studies 
from academia can also be used as additional sources of data in order to improve the models by 
expanding the dataset for model development. 
Case study - Aggregation 
To illustrate the integration in a more practical way, the QSAR implementation is discussed step by 
step using a case study to investigate the aggregation of mAbs. Aggregation is a common CQA that is 
usually investigated as the presence of aggregates are known to cause adverse effects and thus needs to 
be avoided or removed in process development [106, 107]. Refolding of aggregated mAbs can be 
performed in some cases by introducing extra processing steps to refold the protein into the desired 
conformation. However, this will introduce further development and manufacturing costs and prolong 
the production time. As mentioned before, much of the manufacturing cost is incurred in the purification 
of the mAb. 
The purification is also a stage where the mAb is exposed to more extreme environmental 
variations. An example of this is the protein A elution step with low pH (2.5-4.0) to elute bound mAb 
proteins from the chromatographic column. The low pH also allows for virus inactivation which makes 
this a natural step after elution from protein A [108]. However, it has been shown that low pH promotes 
faster protein aggregation of mAbs due to conformational changes or modifications of the structure 
[109, 110]. Thus, this makes an ideal case study for QSAR to investigate the impact of differing protein 
structures on the aggregation during low pH. 
1) Aggregation data can be collected from several mAb processes usually available in past 
characterization studies from either size exclusion chromatography (SEC) or polyacrylamide 
gel electrophoresis (PAGE). For the sake of the case study the example is based on data from 
SEC where the retention profiles and times of high molecular weight species of the mAb 
aggregates are retained. The tested pH ranges are retained and used as inputs (as well as data 
of other tested process parameters in real case studies) in the model development in order to 
investigate their influence on the aggregation. 
2) Descriptors are generated according to the flow chart in Figure 2. An initial approach would 
be to generate descriptors according to the sequence based approach first e.g. with amino acid 
scale and descriptor generating software. The reason for this is that this approach is much faster 
compared to that of the homology/MD based approach, but also that adequate models might be 
generated using the sequence based approach. It should be remembered, however, that 
descriptors generated from MD simulation might be more powerful in explaining the 
underlying mechanism of the aggregation as they are generated based on structural properties 
of the 3D models. 
3) Cleaning and pre-treatment is often necessary before the data can be used for modelling. This 
includes removal of descriptors and process parameters that are static or have missing values. 
Usually, the different variables will have unique ranges with differing magnitudes. In these 
cases, pre-treatment in form of autoscaling should be applied to centre the descriptors around 
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zero and scale them to have a standard deviation of one. This is necessary in order to prevent 
the offset from the origin and variables with large magnitudes to overpower the model and to 
give all descriptors equal chance to contribute to the model output [111]. Variable reduction 
methods can also be applied here to reduce the total number of variables used in the modelling 
by either using decomposition methods such as PCA or correlation studies. However, models 
should be generated from both the reduced and full data sets in order to evaluate if the reduction 
improves the model performance. 
4) Benchmarking of different modelling methods, potentially in combination with descriptor 
selection techniques, should then be carried out to find the optimal modelling solution for the 
problem statement. As mentioned, it is critical to perform proper evaluation of the model 
performance in order to select a model that has good prediction on an external test set and can 
be used for future predictions. A recommendation would be to use Y-randomization to 
investigate if there is an underlying pattern in the variables that is correlated to the output. 
The use of bagging can be especially beneficial in this case and can provide valuable 
information by investigating the uncertainty of the predictions with samples from an external 
test set or new samples acquired in the future. In bagging the prediction will be the averaged 
value based on the predictions from all sub-models for a specified structure and process 
parameter input. From this, further information can be gained by constructing confidence 
intervals that are computed from the individual predictions of all sub-models and provide a 
measure of how certain or uncertain the prediction is. 
In this way, it is possible to assess the influence of the process parameters on the prediction in 
more detail. In case of high uncertainty, the distribution of the predictions will span a wider 
range, which means that further characterization studies are needed to estimate the true 
aggregation probability. This information can later be added to the training of the model in 
order to improve it. In cases of low uncertainty, the range of the prediction distribution will be 
tighter, meaning that all sub-models give similar predictions and characterization studies might 
not be necessary in these cases as the underlying cause is well understood by the model. 
Through this example, we have shown how to integrate the QSAR framework with the QbD paradigm 
to assess the impact of pH (and potentially other process parameters) and the structure of mAbs on the 
aggregation propensity. Many other examples from upstream and downstream could also be used to 
evaluate the impact of structural differences in mAbs on CQAs and CPPs in the process development. 
For example, media design characterization data such as mentioned in the work of Rouiller et al. [26] 
could be used to find similarities in media composition related to structural features of different mAbs. 
Similarly, optimal cell lines for expressing the mAb candidates may be predicted using data as that 
generated by [25]. Data generated from high-throughput screening of chromatographic columns such 
as mentioned in the works of Bhambure et al. [24] and Bhambure and Rathore [30] could be used 
together with QSAR for the prediction of optimal separation and selection of columns . These are a few 
examples that are possible with emerging technologies that can be applied for risk assessment of CQAs 
and PPs using QSAR. The structural similarity of the mAbs is of great advantage and it simplifies the 
analysis of structural differences as compared to other proteins, which makes them ideal for analysis 
with QSAR. 
Conclusions 
In an environment where the regulatory standards are becoming increasingly tighter due to increased 
clinical safety requirements, the biotech industries are forced to raise the bar on quality assurance by 
introducing the QbD paradigm. QbD exploits process understanding to monitor and control only the 
CPPs and raw material attributes that affect CQAs of the product and thus mainly focuses on process 
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understanding. However, a significant limitation of the current implementation of this framework is the 
inability to quantitatively predict the potential processing risks based on the intrinsic properties of the 
pharmaceutical product, as in contrast to the (semi-)empirical risk assessment approaches that are used 
to date. It has been highlighted that considering the intrinsic properties of the product while exploiting 
all the data generated during the process development of different candidates for risk and process 
alternatives assessment, inherits potential for significant cost and time savings, while being fully in line 
with the QbD idea. 
A possible approach that can aid to exploit the potential and reduce the current limitations by 
integrating product knowledge is the QSAR framework. The idea is to link the structural differences 
within the products to the process characterization data to find patterns between structural differences 
and product properties that can be used for risk assessment of product behaviour and process operating 
conditions. With the advancements of in silico methods, their ability to predict complex system 
properties and the impact on product quality, these methods may be used to effectively reduce the 
number of experiments needed to characterize the design space. By using the outlined methods to 
quantify the differences between mAbs and linking those to the process conditions by applying the 
QSAR methodology, process development could be speeded up and costs be reduced.  
The QSAR approach was highlighted as a good candidate to be used together with QbD in order 
to increase both product and process understanding but also to make the implementation of QbD more 
effective.  The current rate of improvement increases the likelihood that in silico methods will become 
an integral part in process development.  
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Supplementary Information 
Table S1. List of popular software used in homology modelling and Molecular Dynamics simulations that has been used for 
antibodies. 
 
  
Homology Modelling Software Developed by Accessibility 
Modeller University of California, San Francisco Free 
Molecular Operating Environment 
(MOE) 
Chemical Computing Group Commercial 
PIGS University of Rome "Sapienza" Free 
RosettaAntibody Gray Lab at John Hopkins University Free 
Molecular Dynamics (MD) Simulation 
Software 
Developed by  Accessibility 
AMBER University of California, San Francisco Commercial 
Desmond Schrödinger Commercial 
GROMACS University of Groningen, Royal Institute of 
Technology and Uppsala University 
Free 
MOE Chemical Computing Group Commercial 
NAMD Theoretical and Computational Biophysics 
Group, University of Illinois 
Free 
Protein RECON Rensselaer Exploratory Center for 
Cheminformatics Research (RECCR) 
Free 
YASARA YASARA Biosciences Commercial 
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Table S2. List of popular MVDA methods and techniques used in QbD and QSAR 
Method Classification/
Regression 
Linear/Non-
linear 
Description Advantages/Disadvantages 
Principal 
Component 
Analysis (PCA) 
Classification Linear The PCA method transforms data into orthogonal linear 
principal components explaining successively reducing 
levels of variance in the data set.  
Advantages: The transformation eliminates collinearity and lowers the 
complexity of the data set by transforming the data into orthogonal principal 
components. Depending on the data, by plotting the scores of two principal 
components against each other PCA can be used to identify clusters of data 
points or gradients. 
Disadvantages: The original variables are linear combination of the principal 
components, wherefore poor performance of PCA on data that contain non-
linear combinations can be expected. 
Linear Discriminant 
Analysis (LDA)  
Classification Both LDA tries to find a hyperplane separating the different 
classes based on a target property. The descriptors are 
used in a linear combination to define the hyperplane 
with the help of a so called linear discriminant functions 
that maximizes the variance between classes and 
minimizes the variance inside of the class. 
 
Advantages: It works well on data that has categorical target properties and 
continuous descriptor variables. The LDA classifier is also easy to implement. 
Disadvantages: Many parameters must be estimated and the model assumes 
that the data are Gaussian distributed even if this is not the case. The 
covariance of all classes is also assumed to be the same. 
k- Nearest 
Neighbours (k-NN) 
Both Not applicable Samples are classified by a distance metric and put into 
the class that the majority of the samples k nearest 
neighbours belongs to. 
Advantages: One of the simplest classifier methods to understand and 
implement.  
Disadvantages: k-NN works best with well separated classes which means 
that classes that overlap have a probability of being misclassified.  
The integer k needs to be optimized to provide a robust model. The number 
of samples in each class have to be equal or similar or the model will be 
biased. 
Decision trees (DT) Both Non-linear DT tries to predict a target class based on several input 
descriptors. It uses a method called recursive 
partitioning that divides the data into subsets by adding 
branching rules based on threshold values for a 
particular descriptor.  
Advantages: The trained classifier has a tree-like structure, which gives it very 
high interpretability as the effects of the descriptors can be seen on the target 
variable. 
Disadvantages: There is usually a problem with over-fitting when using 
decision trees. This makes pruning necessary to remove branches and make 
the model more general. Decision trees are also very sensitive to noise and 
outliers in the data. 
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Method Classification/
Regression 
Linear/Non-
linear 
Description Advantages/Disadvantages 
Multiple Linear 
Regression (MLR) 
 
Regression Linear MLR attempts to establish a linear relationship between 
the input descriptors and the measured output by 
solving for coefficients for each descriptor. 
Advantages: Due to its simplicity, it is a very easy method to implement and 
the generated model is highly interpretable. 
Disadvantages: MLR does not work well when there are a lot of collinearity 
in the descriptor data which can lead to wrongly calculated coefficients. MLR 
also require more samples than descriptors to work properly. 
Principal 
Component 
Regression (PCR) 
 
Regression Linear The PCR method tries to overcome the collinearity 
problem in the descriptor data by use of dimension 
reduction such as in PCA. The generated independent 
principal components are then used to establish a linear 
relationship with the measured output similar to MLR. 
 
Advantages: In descriptor sets with high collinearity the PCR method can 
reduce the data set to dependent principal components that can be used on 
the measured output. 
Disadvantages: The dimension reduction is only dependent on the descriptor 
input data. Meaning, PCR does not consider the possible relationships 
between the descriptors and the measured output before the dimension 
reduction. This can lead to selection of principal components with poor 
relationship with the measured output. 
Partial Least 
Squares (PLS) 
Regression Linear PLS is a method that explains the fundamental 
relationships between input and output data via a 
latent variable space of lower dimension, which is 
constructed such as to maximize the covariance 
between the inputs and outputs. 
Advantages: It is widely used to construct linear models between input and 
output data. Like PCA, PLS eliminates collinearity and also has the advantage 
of being suitable for problems with small sample-sizes.  
PLS exhibits the same disadvantages as PCA. 
Support Vector 
Machines (SVM) 
Both Both When used for regression it is called Support Vector 
Regression (SVR). SVM simplifies the classification by 
transforming the original data into a feature space by 
using kernel functions, which are typically nonlinear. In 
the feature space the data is easier to separate into 
different classes. 
 
Advantages: Two of the main advantages of SVM is 1) its ability to make good 
predictions even with small sample sizes; and 2) the generalization ability of 
the model is high. 
Disadvantages: SVM does not have very good interpretability of how 
descriptors effect the classification due to the transformation in to feature 
space. SVM also requires a lot of tweaking as to which kernel to use and 
optimizing parameters. 
Artificial Neural 
Networks (ANN) 
Both Both Usually ANN consists of neurons in an input layer, 
hidden layer and an output layer. The connections 
between neurons carries a weight that is determined 
during training, thereby weakening or strengthening 
the connection as it learns how to connect the input and 
output data.  
 
Advantages: ANN is a biologically inspired method and has been successfully 
applied to areas such as toxicology, pharmacology and physiochemical 
properties prediction, besides others. The method is able to detect complex 
relationships between descriptors and activity with the use of multiple layers. 
Disadvantages: There can be problems with over-fitting of the training data 
set which decreases the models ability to generalize, thus not accurately 
predicting for samples outside of the training data set. The method can also 
be computationally expensive if the problem is complex. 
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Method Classification/
Regression 
Linear/Non-
linear 
Description Advantages/Disadvantages 
Random Forest (RF) Both Non-linear RF is a technique that uses many decision trees 
explained above. However, the trees are only trained 
with subsets of the descriptors and samples, which 
makes all trees different. Classification is then done by 
a majority rule over all trees. 
 
Advantages: Avoids over-fitting by randomly creating subsets of descriptors 
and samples. It makes the model more generalized and is considered to be 
relatively robust. 
Disadvantages: Due to the majority rule and that all trees are different the 
interpretability of the model is considerably lower. RF can also be 
computational taxing if many trees need to be generated and trained from a 
big data set. 
 
 
 
 
 
 
 
 
 
